Response differences between human CD4(+) and CD8(+) T-cells during CD28 costimulation: implications for immune cell-based therapies and studies related to the expansion of double-positive T-cells during aging.

Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Clin Immunol. 2000 Sep;96(3):187-97. Unique Identifier : AIDSLINE MED/20423206
Laux I; Khoshnan A; Tindell C; Bae D; Zhu X; June CH; Effros RB; Nel A; Division of Clinical Immunology and Allergy, UCLA, Los Angeles,; California, 90095, USA.

Abstract: Since CD28 costimulation is critical for T-cell activation, there is great interest in CD28 as a target for immuntherapeutic approaches. We show that stimulation of human CD4(+) and CD8(+) T-cells differs in their responsiveness to stimulation with anti-CD3/CD28-coated beads, as surrogate antigen-presenting cells. While the CD4(+) subset responded with sustained proliferation, CD8(+) T-cells grew for a limited period only and failed to produce IL-2 beyond the first few days in culture. This decrease is accompanied with an increased rate of apoptosis in CD8(+) T-cells despite Bcl-x(L) expression. The CD8(+) but not the CD4(+) subset developed a reversible double-positive phenotype during CD28 costimulation. This finding may have some bearing on the appearance of double-positive T-cells in human peripheral blood. This double-positive subset was shown to undergo a statistically significantly increase during aging in humans. Taken together, the above data have important implications for immunotherapy and immune senescence. Copyright 2000 Academic Press.

Keywords: JOURNAL ARTICLE Adult Aged Aged, 80 and over Aging/GENETICS/PHYSIOLOGY Antigens, CD28/*IMMUNOLOGY/*PHYSIOLOGY CD4-Positive T-Lymphocytes/*IMMUNOLOGY CD8-Positive T-Lymphocytes/*IMMUNOLOGY Human HLA-DP Antigens/BLOOD/GENETICS Immunotherapy, Adoptive/METHODS Lymphocyte Transformation/IMMUNOLOGY Phenotype Support, U.S. Gov't, P.H.S.

001230
A00C0901

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .